Last reviewed · How we verify
NCT04663880
Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma
NA trial testing Exposure to placebo in EEC in Allergic Asthma in 27 participants. Completed in 15 February 2017.
23 January 2017
Quick facts
| Lead sponsor | Alyatec |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 27 |
| Start date | 30 August 2016 |
| Primary completion | 23 January 2017 |
| Estimated completion | 15 February 2017 |
| Sites | 1 location across France |
Drugs / interventions tested
- Exposure to placebo in EEC
- Exposure to three concentrations of HDM allergen in EEC
- Exposure to a single concentration of HDM allergen in EEC
Conditions studied
- Allergic Asthma — all drugs for Allergic Asthma →
- Allergy to House Dust — all drugs for Allergy to House Dust →
- Allergy — all drugs for Allergy →
Sponsor
Alyatec
Who can join
Adults 18 to 50, any sex, with Allergic Asthma or Allergy to House Dust. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne house dust mite allergen inducing bronchial response in asthmatic subjects allergic to mite, during allergen exposures in the Alyatec environmental exposure chamber (EEC). The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne house dust mite allergen in Alyatec EEC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04663880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Asthma
Currently open trials in the same condition.
- NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
- NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
- NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
- NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting
- NCT06771934 — Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma · active not recruiting
Other Alyatec trials
Trials by the same sponsor.
- NCT06104293 — Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass · NA · completed
- NCT06267261 — Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber · NA · completed
- NCT04583202 — Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Expo · NA · completed
- NCT03928561 — Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber · NA · completed
- NCT04641130 — Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04663880 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alyatec
- Last refreshed: 11 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04663880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing